Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebaloxavir Marboxil for Influenza Prevention in Household Contacts
NCT07730346Phase 3Not yet recruiting
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Sebaloxavir marboxil group with Placebo group (2 arms). Primary endpoint: Percentage of household contacts with PCR-positive influenza virus infection accompanied by fever and at least one additional influenza symptom at 10 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07730346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730346.